Xencor Inc. Files 8-K Report
Ticker: XNCR · Form: 8-K · Filed: Oct 24, 2025 · CIK: 1326732
| Field | Detail |
|---|---|
| Company | Xencor Inc (XNCR) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
Related Tickers: XNCR
TL;DR
Xencor filed an 8-K, likely containing important updates. Check for details.
AI Summary
On October 24, 2025, Xencor Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Xencor Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific financial or operational details that would indicate immediate risk.
Key Players & Entities
- Xencor Inc. (company) — Registrant
- October 24, 2025 (date) — Date of Report
- 465 North Halstead Street, Suite 200 Pasadena, California 91107 (address) — Principal Executive Offices
FAQ
What specific information is being disclosed in this 8-K filing?
The filing is categorized under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', but the specific details of the disclosure are not provided in this excerpt.
When was this 8-K report filed?
The report was filed on October 24, 2025.
What is Xencor Inc.'s principal executive office address?
Xencor Inc.'s principal executive offices are located at 465 North Halstead Street, Suite 200, Pasadena, California 91107.
What is Xencor Inc.'s IRS Employer Identification Number?
Xencor Inc.'s IRS Employer Identification Number is 20-1622502.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 664 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2025-10-24 13:57:11
Key Financial Figures
- $0.01 — ich Registered Common Stock, par value $0.01 per share XNCR Nasdaq Global Market I
Filing Documents
- xncr-20251024.htm (8-K) — 27KB
- xncr-2025x1024xexx991.htm (EX-99.1) — 36KB
- xncr-20251024xexx992.htm (EX-99.2) — 17KB
- image_0a.jpg (GRAPHIC) — 17KB
- xncr-2025x1024xexx991001.jpg (GRAPHIC) — 55KB
- xncr-2025x1024xexx991002.jpg (GRAPHIC) — 69KB
- xncr-2025x1024xexx991003.jpg (GRAPHIC) — 82KB
- xncr-2025x1024xexx991004.jpg (GRAPHIC) — 235KB
- xncr-2025x1024xexx991005.jpg (GRAPHIC) — 156KB
- xncr-2025x1024xexx991006.jpg (GRAPHIC) — 119KB
- xncr-2025x1024xexx991007.jpg (GRAPHIC) — 126KB
- xncr-2025x1024xexx991008.jpg (GRAPHIC) — 98KB
- xncr-2025x1024xexx991009.jpg (GRAPHIC) — 48KB
- xncr-2025x1024xexx991010.jpg (GRAPHIC) — 127KB
- xncr-2025x1024xexx991011.jpg (GRAPHIC) — 107KB
- xncr-2025x1024xexx991012.jpg (GRAPHIC) — 114KB
- xncr-2025x1024xexx991013.jpg (GRAPHIC) — 76KB
- xncr-2025x1024xexx991014.jpg (GRAPHIC) — 92KB
- xncr-2025x1024xexx991015.jpg (GRAPHIC) — 128KB
- xncr-2025x1024xexx991016.jpg (GRAPHIC) — 154KB
- xncr-2025x1024xexx991017.jpg (GRAPHIC) — 130KB
- xncr-2025x1024xexx991018.jpg (GRAPHIC) — 128KB
- xncr-2025x1024xexx991019.jpg (GRAPHIC) — 75KB
- xncr-2025x1024xexx991020.jpg (GRAPHIC) — 91KB
- xncr-2025x1024xexx991021.jpg (GRAPHIC) — 188KB
- xncr-2025x1024xexx991022.jpg (GRAPHIC) — 148KB
- xncr-2025x1024xexx991023.jpg (GRAPHIC) — 40KB
- xncr-2025x1024xexx991024.jpg (GRAPHIC) — 122KB
- xncr-2025x1024xexx991025.jpg (GRAPHIC) — 98KB
- xncr-2025x1024xexx991026.jpg (GRAPHIC) — 128KB
- xncr-2025x1024xexx991027.jpg (GRAPHIC) — 102KB
- xncr-2025x1024xexx991028.jpg (GRAPHIC) — 146KB
- xncr-2025x1024xexx991029.jpg (GRAPHIC) — 108KB
- xncr-2025x1024xexx991030.jpg (GRAPHIC) — 49KB
- xncr-2025x1024xexx991031.jpg (GRAPHIC) — 139KB
- xncr-2025x1024xexx991032.jpg (GRAPHIC) — 71KB
- xncr-2025x1024xexx991033.jpg (GRAPHIC) — 145KB
- xncr-2025x1024xexx991034.jpg (GRAPHIC) — 33KB
- xncr-2025x1024xexx991035.jpg (GRAPHIC) — 133KB
- xncr-2025x1024xexx991036.jpg (GRAPHIC) — 30KB
- xncr-2025x1024xexx991037.jpg (GRAPHIC) — 55KB
- 0001326732-25-000082.txt ( ) — 5676KB
- xncr-20251024.xsd (EX-101.SCH) — 2KB
- xncr-20251024_lab.xml (EX-101.LAB) — 21KB
- xncr-20251024_pre.xml (EX-101.PRE) — 12KB
- xncr-20251024_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. Xencor, Inc. (the "Company") held a conference call on October 24, 2025 to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819 (ENPP3 x CD3), early data from the ongoing Phase 1 dose-escalation study of XmAb541 (CLDN6 x CD3), and associated near-term clinical timelines. The Company has also made available on its website (www.xencor.com) presentation materials containing certain data from the ongoing clinical studies and certain forward-looking information. The information contained in, or that can be accessed through, the Company's website is not a part of this filing. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The presentation is current as of April 29, 2025 and the Company disclaims any obligation to update this material. On October 24, 2025, the Company issued a press release announcing the initial results from the ongoing Phase 1 dose-escalation study of XmAb819 (ENPP3 x CD3) and associated near-term clinical timelines. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. The information furnished under this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Presentation dated October 24, 2025. 99.2 Press release issued by Xencor, Inc. on October 2 4 , 2025. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 24, 2025 XENCOR, INC. By: /s/ Celia Eckert Celia Eckert General Counsel & Corporate Secretary